Alterity Therapeutics

Yahoo Finance • 20 days ago

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

ALTERITY THERAPEUTICS LIMITED MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease... Full story

Yahoo Finance • 2 months ago

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026. Claassen is Professor of Neurology at Vanderbilt University Medical Center, where he... Full story

Yahoo Finance • 6 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neur... Full story

Yahoo Finance • 7 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance unders... Full story

Yahoo Finance • 7 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE... Full story

Yahoo Finance • 8 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neu... Full story

Yahoo Finance • 8 months ago

Alterity Therapeutics raises A$20 million in strategic placement

* Alterity Therapeutics (NASDAQ:ATHE [https://seekingalpha.com/symbol/ATHE]) on Monday said it has received binding commitments for a capital raising of A$20.0 million of fully paid ordinary shares to International and Australian profess... Full story

Yahoo Finance • 8 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neu... Full story

Yahoo Finance • 8 months ago

Alterity Therapeutics to Present at the Biotech Showcase

MELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neu... Full story

Yahoo Finance • 9 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented additional analyses from the ATH434-201 tr... Full story

Yahoo Finance • 9 months ago

Alterity reports data from multiple system atrophy study

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images... Full story

Yahoo Finance • 9 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated with Favorabl... Full story

Yahoo Finance • 4 years ago

UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd

Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conferenc... Full story